Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer
Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer
The purpose of this study is to test the ability of a breast MRI biopsy to accurately
 diagnose a complete tumor response to the neoadjuvant chemotherapy (NAC) that the patient
 just finished. Numerous studies have shown that MRI has the highest accuracy for diagnosing a
 complete tumor response. The investigator wants to see if in a certain group of women who's
 breast cancer is no longer visible on the post-treatment MRI that the biopsy specimens from a
 MRI guided biopsy will accurately diagnose a complete tumor response to treatment which may
 in the future make breast surgery unnecessary in some women.
Inclusion Criteria:

 -  Women age 18 years or older

 -  Confirmed histologic diagnosis of operable HER2 overexpressing (ER<10%, PR<10%, and
 HER2 2+ or FISH amplified) OR triple negative (ER<10%, PR<10%, and HER2 0/1+ or
 2+/FISH not amplified) OR ER positive invasive ductal or invasive lobular breast
 cancer including MSKCC pathology confirmation

 -  Operable breast cancer treated with NAC undergoing either breast conservation or total
 Mastectomy who have had a post-NAC clinical bilateral breast MRI demonstrating a
 complete imaging response, which is defined as no residual tumor enhancement.

 -  No indication of distant metastases (M0)

 -  Tumor site amenable to MRI guided biopsy as determined by the radiologist

 -  Definitive surgery being performed at MSKCC within within 0-60 days of completing NAC

 -  ECOG performance status score of 0 to ≤ 2 and or KPS performance status score of 80%
 to 100%

 -  Women of childbearing potential (WOCBP) must not be pregnant.

 -  Women must not be breastfeeding

 -  Willing and able to provide informed consent and adhere to the study visit schedule
 and plan as specified in this protocol

 Exclusion Criteria:

 -  Medical history and concurrent disease:

 -  Prior history of treated breast cancer

 -  Any underlying medical or psychiatric conditions, which in the opinion of the
 investigator, will make performing the study intervention hazardous or obscure
 the interpretation of the results

 -  Prohibited Treatments and/or Therapies:

 -  Prior history of breast cancer surgery and/or radiotherapy.